

[Day 1] November 30 (Thursday)

Room 1 (4F Hall)

Industrial Lunchtime Seminar 1

Co-sponsored by Johnson & Johnson K.K.

Date and Time: November 30 (Thursday) 12:00~12:50

Session Room: Room 1 (4F Hall)

Chairperson: Hirotaka Nishi

(Department of Obstetrics and Gynecology, Tokyo Medical University, Japan)

ILS1-1 How to improve the skills and coordinate laparoscopic surgery for endometrial cancer: Difficulties for oncologists who are familiar with laparotomy, rather than laparoscopy

Katsutoshi Oda

(Department of Obstetrics and Gynecology, Faculty of Medicine, The University of Tokyo, Japan)

ILS1-2 Innovation and invention in laparoscopic surgery for gynecologic tumors

Eiji Kobayashi

(Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Japan)

Symposium 1

Extensive and Robotic Surgery

Date and Time: November 30 (Thursday) 13:10~15:00

Session Room: Room 1 (4F Hall)

Chairpersons: Rongyu Zang

(Ovarian Cancer Program, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Zhongshan Hospital, Fudan University, China)

Mikio Mikami

(Department of Obstetrics and Gynecology, Tokai University, School of Medicine, Japan)

SY1-1 Robotic surgery for gynecological cancers

Masaki Mandai

(Department of Gynecology and Obstetrics, Kyoto University Graduate School of Medicine, Japan)

SY1-2 Radical surgery for the pelvic side wall tumors in gynecologic cancers

Hee Seung Kim

(Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Korea)

SY1-3 Extensive surgery and robotic surgery for gynecologic oncology

Kung-Liahng Wang

(Taitung Mackay Memorial Hospital, Taiwan)

SY1-4 Surgery for stage IIB cervical cancer: Role of radical surgery

Mikio Mikami

(Department of Obstetrics and Gynecology, Tokai University, School of Medicine, Japan)

Invited Lecture 1**P**

Date and Time: November 30 (Thursday) 15:20~16:20

Session Room: Room 1 (4F Hall)

Chairpersons: Toshiharu Kamura

(MCER Foundation, Professor Emeritus, Kurume University, Japan)

Aikou Okamoto

(Department of Obstetrics and Gynecology, The Jikei University School of Medicine, Japan)

IL1-1 Translational model for precision medicine in gynecologic cancer

Duk-Soo Bae

(Department of Obstetrics & Gynecology, Samsung Medical Center, Department of Obstetrics and Gynecology, Sungkyunkwan University School of Medicine, Korea)

IL1-2 Global teaching and training in gynaecological oncology

Michael Quinn

(President, International Gynecologic Cancer Society, Australia)

Presidential Lecture

Date and Time: November 30 (Thursday) 16:20~16:50

Session Room: Room 1 (4F Hall)

Chairperson: Joo-Hyun Nam

(Professor Emeritus, Department of Obstetrics and Gynecology, Asan Medical Center, Korea, University of Ulsan, Korea)

PL Surgery for recurrent gynecologic cancer

Ikuo Konishi

(President of ASGO, Professor Emeritus of Kyoto University, Japan)

Symposium 2

Precision Medicine

Date and Time: November 30 (Thursday) 17:10~18:40

Session Room: Room 1 (4F Hall)

Chairpersons: Ting-Chang Chang

(Chang Gung Memorial Hospital Linkou Medical Center, Chang Gung University Medical College, Taiwan)

Kiyoko Kato

(Department of Obstetrics and Gynecology, Graduate School of Medical Science, Kyushu University, Japan)

SY2-1 Precision gynecologic oncology in Taiwan

Ting-Chang Chang

(Chang Gung Memorial Hospital Linkou Medical Center, Chang Gung University Medical College, Taiwan)

SY2-2 Synthetic lethality in ovarian cancer

Kosuke Yoshihara

(Department of Obstetrics and Gynecology, Niigata University Graduate School of Medical and Dental Sciences, Japan)

SY2-3 Molecular profiling and precision medicine in gynecologic cancer

Katsutoshi Oda

(Department of Obstetrics and Gynecology Graduate School of Medicine, The University of Tokyo, Japan)

SY2-4 Histology-specific expression of *HOX* for a tailored chemoresistance-overcoming strategy in epithelial ovarian cancer: Paclitaxel carboplatin does not fit all ovarian cancer any more

Dong Hoon Suh

(Department of Obstetrics and Gynecology, Seoul National University Bundang Hospital, Korea)

SY2-5 Deciphering intra-tumoral heterogeneity using molecular assessment of subtype heterogeneity to guide personalized medicine in ovarian cancer

Ruby Yun-Ju Huang

(Translational Centre for Development and Research (Transcend), Cancer Science Institute of Singapore, Department of Obstetrics & Gynaecology, Department of Anatomy, Yong Yoo Lin School of Medicine, National University of Singapore, Singapore)

Room 2 • 3 (3F 301~304)

Endometrial Cancer 1

Date and Time: November 30 (Thursday) 13:10~13:50

Session Room: Room 2 • 3 (3F 301~304)

Chairpersons: Efren Domingo

(University of the Philippines, Philippines)

Tsuyoshi Saito

(Department of Obstetrics and Gynecology, Sapporo Medical University, Japan)

O1-1 Exploring a novel epigenetic therapy with inhibition of histone methyltransferase SETD8 for endometrial cancer

Shinya Oki

(Department of Obstetrics and Gynecology, Faculty of Medicine, The University of Tokyo, Japan)

O1-2 Correlation between preoperative office endometrial biopsy and final histological diagnosis by surgical specimen on uterine endometrial cancer

Takaya Shiozaki

(Hyogo Cancer Center, Japan)

O1-3 Hysteroscopic indocyanine green injection for sentinel lymph node mapping of endometrial cancer

Wei Li

(Department of Gynecologic Oncology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, China)

O1-4 Is there a survival advantage in diagnosing endometrial cancer in asymptomatic postmenopausal patients? An Israeli Gynecology Oncology Group Study

Ofer Gerner

(Barzilai Medical Center, Faculty of Health Sciences, Ben Gurion University, Israel)

Endometrial Cancer 2

Date and Time: November 30 (Thursday) 13:50~14:40

Session Room: Room 2 • 3 (3F 301~304)

Chairpersons: Toru Hachisuga

(Department of Obstetrics and Gynecology, University of Occupational and Environmental Health, Japan)

Kimihiko Ito

(Department of Obstetrics and Gynecology, Kansai Rosai Hospital, Japan)

O2-1 Long-term outcomes of medroxyprogesterone acetate plus metformin as fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer

Akira Mitsuhashi

(Department of Reproductive Medicine, Graduate School of Medicine, Chiba University, Japan)

- O2-2** An evaluation of sequential multi-modality adjuvant chemotherapy and radiation in the “sandwich” method for the treatment of advanced endometrial cancer
Guo Zhang
(Peking University People’s Hospital, China)
- O2-3** Phase II study of irinotecan hydrochloride (CPT-11) in patients with advanced or recurrent endometrial cancer
Shin Nishio
(Department of Obstetrics and Gynecology, Kurume University School of Medicine, Japan)
- O2-4** Microsatellite instability is potential biomarker for immune checkpoint inhibitors (anti-PD-1/PD-L1 antibody) in endometrial cancer
Hitomi Yamashita
(Department of Obstetrics and Gynecology, Shimane University School of Medicine, Japan)
- O2-5** The adjuvant therapy for high-risk endometrial cancer: A retrospective multicenter collaborative study between China and Japan (FUSCC-EC1402/KCOG-G1401)
Yulan Ren
(Department of Gynecologic Oncology, Fudan University Shanghai Cancer Center, China)

TR Others 1

Date and Time: November 30 (Thursday) 15:20~16:10

Session Room: Room 2・3 (3F 301~304)

Chairpersons: Chunling Chen

(The President of SOG-CPAM (Society of Ob/Gyn, China International Exchange and Trade Promotion Association for Medical and Health Care))

Tanri Shiozawa

(Department of Obstetrics and Gynecology, Shinshu University, School of Medicine, Japan)

- O3-1** Curcumin anticancer effect in gynecological cancer cells is enhanced by AKT-mTOR pathway activity
Tze Fang Wong
(Department of Obstetrics and Gynecology, St. Marianna University School of Medicine, Japan)
- O3-2** Examination of preoperative diagnosis using exosomes for uterine leiomyosarcoma
Takuma Hayashi
(Shinshu University School of Medicine, Japan)
- O3-3** Long non-coding RNA steroid receptor activator increases cell proliferation and invasion and predicts patient prognosis in the human cervical cancer
Hee Jung Kim
(Department of Obstetrics and Gynecology, Institute of Women’s Life Medical Science, Korea)

- O3-4 Fully-sialylated alpha-chain of complement 4-binding protein (C4BP): A novel prognostic biomarker for epithelial ovarian cancer**

Masae Ikeda

(Tokai University School of Medicine, Japan)

- O3-5 Oral thrombopoietin receptor (TPO-R) agonist, eltrombopag: Is it a possible solution of chemotherapy induced thrombocytopenia in gynecologic cancer?**

Hao Hsu

(Department of Obstetrics and Gynecology, Chang Gung Memorial Hospital at Linkou, Taiwan)

TR Others 2

Date and Time: November 30 (Thursday) 16:10~16:50

Session Room: Room 2 · 3 (3F 301~304)

Chairpersons: Chyong-Huey Lai

(Gynecologic Cancer Research Center, Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Taiwan)

Kaneyuki Kubushiro

(Department of Obstetrics and Gynecology, Toho University Omori Medical Center, Japan)

- O4-1 Coexisting cancers with atypical glandular abnormalities: A retrospective study in large hospital-based**

Malika Kengsakul

(Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thailand)

- O4-2 Uterine adenomatoid tumor: A neoplasm having frequent association with immunosuppressive therapy**

Daisuke Tamura

(Department of Obstetrics and Gynecology, Graduate School of Medicine, Akita University, Japan)

- O4-3 Retrospective clinicopathological study of uterine smooth muscle tumor of uncertain malignant potential (STUMP) and revising diagnosis: An analysis of 30 cases**

Chao Gu

(OB & GYN Hospital, Fudan University, China)

- O4-4 Prognostic factors in patients with vulvar cancer treated with primary surgery: A single center experience**

Yuko Shimoji

(University of the Ryukyus, Japan)

Young Doctors' Session 1

Date and Time: November 30 (Thursday) 17:10~18:00

Session Room: Room 2 · 3 (3F 301~304)

Chairpersons: Jatupol Srisomboon

(Department of Obstetrics & Gynecology, Faculty of Medicine, Chiang Mai University, Thailand)

Satoru Nagase

(Department of Obstetrics and Gynecology, Yamagata University, Faculty of Medicine, Japan)

- YD1-1** Maspin expression related with hypoxia affects prognosis of clear cell carcinoma of the ovary
Soo Jin Park
(Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Korea)
- YD1-2** Low concentration of chloroquine enhanced efficacy of cisplatin in the treatment of human ovarian cancer dependent on autophagy
Jie Zhu
(Obstetrics and Gynecology Hospital of Fudan University, China)
- YD1-3** PD-L1 disruption by CRISPR/Cas9-mediated genome editing in tumor cells promotes antitumor immunity and suppresses ovarian cancer progression in a mouse model
Tamaki Yahata
(Department of Obstetrics and Gynecology, Wakayama Medical University, Japan)
- YD1-4** Anti-CD40 antibody and toll-like receptor 3 ligand enhance antigen-specific immunity and anti-tumor effects of mesothelin-specific chimeric DNA vaccine
Heng-Cheng Hsu
(Department of Obstetrics and Gynecology, National Taiwan University Hospital Hsin-Chu Branch, Taiwan)
- YD1-5** The role of albumin level, obesity and ascites as morbidity risk factors after ovarian carcinoma surgery
Aditya Zulfikar
(Obstetric & Gynecology Departement, Faculty of Medicine, Hasanuddin University, Indonesia)

Young Doctors' Session 2

Date and Time: November 30 (Thursday) 18:00~18:40

Session Room: Room 2・3 (3F 301~304)

Chairpersons: Kenichiro Morishige

(Department of Obstetrics and Gynecology, University of Gifu, Japan)

Yoshihito Yokoyama

(Department of Obstetrics and Gynecology, Hirosaki University, Japan)

YD2-1 Survival outcomes in different subtypes of epithelial ovarian cancer patients

Kewalin Kobwitaya

(Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Faculty of Medicine, Chulalongkorn University, Thailand)

YD2-2 Correlation of residual disease and survival in germline BRCA mutation-associated ovarian cancer

Tingyan Shi

(Ovarian Cancer Program, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Zhongshan Hospital Fudan University, China)

YD2-3 Mutated exon level in BRCA1 may influence the clinical course of BRCA1-associated epithelial ovarian cancer

Kyung Jin Eoh

(Institute of Women's Life Medical Science, Women's Cancer Center, Department of Obstetrics and Gynecology, Yonsei University College of Medicine, Korea)

YD2-4 Outcomes of women with stage 3 endometrioid adenocarcinoma of the uterus treated with adjuvant chemotherapy and radiotherapy

Yu Hui Lim

(KK Women's and Children's Hospital, Singapore)

Poster Exhibition

Date and Time: November 30 (Thursday) 10:00~18:00

Session Room: Poster Exhibition (3F · 4F Foyer)

Poster Exhibition

Group 1; Cervical Cancer; Early Stage

- P1-1-1** Clinical-pathological characteristics of microscopic stage Ib1 cervical cancer postoperative radical hysterectomy
Jianguo Zhao
(Tianjin Central Hospital of OBS & BYN, China)
- P1-1-2** Preoperative prediction model for parametrial invasion in women with early-stage cervical cancer
Kittipat Charoenkwan
(Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Faculty of Medicine, Chiang Mai University, Thailand)
- P1-1-3** Pelvic lymph node metastasis and non-squamous histology can estimate parametrial invasion in early stage cervical cancers
Fuminori Ito
(Nara Prefecture General Medical Center, Japan)
- P1-1-4** Comparison of MRI, PET-CT, and frozen biopsy in the evaluation of lymph node status before fertility-sparing radical trachelectomy in early stage cervical cancer
Jeong-Yeol Park
(Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center, Korea)
- P1-1-5** Safety analysis of negative margins after conization in the patients with microinvasive squamous cell carcinoma of uterine cervix
Miseon Kim
(Department of Obstetrics and Gynecology, Seoul National University Bundang Hospital, Korea)
- P1-1-6** Effectiveness and safety of radical parametrectomy and pelvic lymphadenectomy for occult invasive cervical carcinoma found after inadvertent simple hysterectomy
Uraivan Khomphaiboonkij
(Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Faculty of Medicine, Chiang Mai University, Thailand)
- P1-1-7** Radical trachelectomy for early stage cervical cancer: A case series and literature review
Kuan-Ju Huang
(Department of Obstetrics and Gynecology, National Taiwan University Hospital, Taiwan)
- P1-1-8** The safety and the efficacy of laparoscopic surgery for early stage uterine cervical cancer: Preliminary results from Osaka University Hospital
Seiji Mabuchi
(Dept of OBGYN, Osaka University Graduate School of Medicine, Japan)

- P1-1-9 Asian body mass index benchmark for total laparoscopic radical hysterectomy procedure in early stage of cervical cancer treatment: risk, complication, outcomes**

Florencia Wirawan

(Gynecology Oncology Division, Fatmawati General Hospital, Indonesia)

- P1-1-10 Dilemma of young gynecologist oncologist in low-resource setting: Does complications of total laparoscopic radical hysterectomy pelvic lymphadenectomy worth the outcome of early-stage cervical cancer patients?**

Florencia Wirawan

(Gynecology Oncology Division, OB/GYN Department, Fatmawati General Hospital, Indonesia)

Poster Exhibition

Group 2; Cervical Cancer; Advanced and Recurrence

- P1-2-1 Prognostic factors and treatment outcome for patients with stage IVB cervical cancer**

Yusuke Taira

(Department of Obstetrics and Gynecology, Graduate School of Medicine, University of the Ryukyus, Japan)

- P1-2-2 Clinical characteristics of stage IVB cervical cancer with hematogenous metastasis: a retrospective study and review of pertinent literature**

Xi Cheng

(Fudan University Shanghai Cancer Center, China)

- P1-2-3 Predictive value of neutrophil/lymphocyte ratio in stage IVB or recurrent or persistent**

Pornprom Ittiamornlert

(Gynecologic Oncology Division, Department of Obstetrics & Gynecology, Faculty of Medicine, Siriraj Hospital, Thailand)

- P1-2-4 Experience of pretreatment laparoscopic para-aortic lymph node sampling in patients with locally advanced cervical cancer**

Kenrokuro Mitsube

(Obstetrics and Gynecology, Hokkaido P.W.F.A.C. Asahikawa-Kosei General Hospital, Japan)

- P1-2-5 Clinical pathology achieved almost complete remission of local advanced cervical cancer after neoadjuvant chemotherapy: analysis of 25 patients**

Gu-Qun Shen

(The Affiliated Tumor Hospital of Xinjiang Medical University, China)

- P1-2-6 Radiation therapy for extrapelvic lymph node recurrence after curative treatment for cervical cancer**

Takashi Uno

(Department of Diagnostic Radiology and Radiation Oncology, Graduate School of Medicine, Chiba University, Japan)

P1-2-7 The effect of intravenous sedation for late rectal hemorrhage in intracavitary radiotherapy for cervical cancer

Miho Watanabe

(Diagnostic Radiology and Radiation Oncology, Graduate School of Medicine, Chiba University, Japan)

Poster Exhibition

Group 3; Cervical Cancer; Chemotherapy, Radiation and CCRT

P1-3-1 A retrospective study of combination chemotherapy with bevacizumab treatment in cervical cancer

Suguru Odajima

(Department of Obstetrics and Gynecology, The Jikei University School of Medicine, Japan)

P1-3-2 Novel effects of narrow band low-energy middle infrared radiation in enhancing the anti tumor activity of paclitaxel

Bor-Ching Sheu

(Department of Obstetrics & Gynecology, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taiwan)

P1-3-3 Impact of adjuvant hysterectomy on prognosis in patients with locally advanced cervical cancer treated with concurrent chemoradiotherapy: A meta-analysis

Seung-Hyuk Shim

(Department of Obstetrics and Gynecology, Konkuk University School of Medicine, Korea)

P1-3-4 Short term outcomes of helical tomotherapy in the concurrent chemoradiotherapy (CCRT) for the advanced cervical carcinoma

Yasushi Mabuchi

(Department of Obstetrics and Gynecology, Wakayama Medical University, School of Medicine, Japan)

P1-3-5 Study of non-hematologic toxicity of adjuvant concurrent chemoradiotherapy (CCRT) after type 3 radical hysterectomy for cervical cancer

Masahiro Ezawa

(Department of Obstetrics and Gynecology, The Jikei University School of Medicine, Japan)

P1-3-6 Concurrent weekly cisplatin versus triweekly cisplatin with radiotherapy for locally advanced squamous-cell carcinoma of the cervix: A retrospective analysis from a single institution

Yoshino Kinjyo

(Department of Obstetrics and Gynecology, Graduate School of Medical Science, University of the Ryukyus, Japan)

P1-3-7 Survival outcomes of neoadjuvant chemotherapy followed by radical hysterectomy versus concurrent chemoradiation in patients with locally advanced cervical cancer

Hyun-Woong Cho

(Department of Obstetrics and Gynecology, Korea University Medical Center, Guro Hospital, Korea)

Poster Exhibition

Group 4; Cervical Cancer; Case Report

- P1-4-1** Villoglandular adenocarcinoma of the uterine cervix: A clinicopathological study of 9 cases
Huang, Zhuo Ya
(Department of Pathology, The Huizhou Municipal Central Hospital, China)
- P1-4-2** Withdrawal
- P1-4-3** A rare case of cervical alveolar soft part sarcoma in young woman presenting with abnormal uterine bleeding: A case report
Putri Deva Karimah
(Department of Obstetrics and Gynaecology, Faculty of Medicine, Universitas Indonesia, Indonesia)
- P1-4-4** Nerve sparing radical parametrectomy using da Vinci Xi robotic system: A case report and review of the literature
San Hui Lee
(Department of Obstetrics and Gynecology, Yonsei University Wonju College of Medicine, Korea)

Poster Exhibition

Group 5; Endometrial Cancer; Basic and Preclinical Research

- P1-5-1** Mutation analysis by whole exome sequencing of endometrial hyperplasia and carcinoma from one patient
Koichi Ida
(Shinshu University, Japan)
- P1-5-2** Studying the associations between LYVE-1, Prox-1, and lymphatic metastasis in endometrial carcinoma
Caiyan Liu
(Department of Gynecological Oncology, Tianjin Central Hospital of Gynecology & Obstetrics, China)
- P1-5-3** Loss of tricellular tight junction protein LSR promotes cell invasion and migration via upregulation of TEAD1/AREG in human endometrial cancer
Hiroshi Shimada
(Department of Obstetrics and Gynecology, Sapporo Medical University School of Medicine, Japan)
- P1-5-4** Metabolomic analysis of uterine serous carcinoma with acquired resistance to paclitaxel
Manabu Seino
(Yamagata University, Japan)
- P1-5-5** Investigation of cell cycle regulatory marker as a potential prognostic biomarker in uterine carcinosarcoma
Min-Hyun Baek
(Hallym University Sacred Heart Hospital, Korea)

P1-5-6 Measurement of endometrial thickness in premenopausal women in office gynecology-MET (mean endometrial thickness) study group

Hiroshi Tsuda

(Mizuho Women's Clinic, Japan)

Poster Exhibition

Group 6; Endometrial Cancer; Diagnosis and Prognosis

P1-6-1 Utility of resectoscopy and laparoscopy before initiating fertility-persevering treatment in early endometrial cancer: a single institutional experience

KimSeng Law

(Department of Obstetrics and Gynecology, Taiwan)

P1-6-2 Incidence and prognostic effect of positive peritoneal cytology in patients with endometrial carcinoma after hysteroscopy vs. dilatation and curettage

Yoo-Kyung Lee

(Department of Obstetrics and Gynecology, Cheil General Hospital, College of Medicine, Dankook University, Korea)

P1-6-3 Prediction of myometrial invasion in stage I endometrial cancer by MRI

Le, Tien Hsu

(Chang Gung Memorial Hospital, Taiwan)

P1-6-4 Diagnostic value of serum human epididymal secretory protein4 in stage I endometrial carcinoma

Shuli Yang

(Department of Gynecologic oncology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, China)

P1-6-5 Utility of p16, ER, Vimentin and CEA expression in differential diagnosis between endocervical and endometrial adenocarcinomas

Jong Hee Nam

(Department of Pathology, Korea)

P1-6-6 The feasibility of detecting endometrial and ovarian cancer using DNA methylation biomarkers in cervical scrapings

Cheng-Chang Chang

(Department of Obstetrics and Gynecology, Tri-Service General Hospital, National Defense Medical Center, Taiwan)

P1-6-7 Insulin resistance affects therapeutic effect of fertility-sparing treatment in patients with endometrial atypical hyperplasia

Bingyi Yang

(The Obstetrics and Gynecology Hospital of Fudan University, China)

Poster Exhibition

Group 7; Ovarian Cancer; Preclinical Research

- P1-7-1** The role of apoptosis repressor with caspase recruitment domain (ARC) in ovarian cancer tumorigenesis and chemoresistance
Jing Zhu
(Department of Obstetrics and Gynecology, Shanghai Obstetrics and Gynecology Hospital, Fudan University, China)
- P1-7-2** Epithelial ovarian cancer progression promoted by vitamin D binding protein in regulation of insulin-like growth factor-1/Akt activities
Yu-Fang Huang
(Department of Obstetrics and Gynecology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Taiwan)
- P1-7-3** Impact of natural killer cell subsets on ovarian cancer
Ling Lim
(Department of Obstetrics and Gynecology, MacKay Memorial Hospital, Taiwan)
- P1-7-4** Aurora-A inhibition synergistically enhances cisplatin induced cytotoxicity in ovarian clear cell carcinoma cell lines
Yohei Chiba
(Iwate Prefectural Ninohe Hospital, Japan)
- P1-7-5** N-myc downstream regulated gene-1 may play an important role in prognosis of ovarian cancer
Atsumu Terada
(Department of Obstetrics and Gynecology, Kurume University School of Medicine, Japan)
- P1-7-6** Upregulated exosomal miR-99a-5p can be a potential biomarker of ovarian cancer and promotes cancer cell invasion by increasing PAI-1 expression in neighboring peritoneal mesothelial cells
Akihiko Yoshimura
(Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Japan)
- P1-7-7** Clinical correlation of mucosal-associated invariant T cells in ovarian cancer
Chih-Long Chang
(Department of Obstetrics and Gynecology, MacKay Memorial Hospital, Taiwan)
- P1-7-8** Integrating the dysregulated inflammasome-based molecular functionome in the malignant transformation of endometriosis-associated ovarian carcinoma
Cheng-Chang Chang
(Department of Obstetrics and Gynecology, Tri-Service General Hospital, National Defense Medical Center, Taiwan)
- P1-7-9** Diagnosis of early stage ovarian clear cell carcinoma (OCCC) using fully-sialylated C4-binding protein index (FS-C4BP index)
Masaru Hayashi
(Department of Obstetrics and Gynecology, Tokai University School of Medicine, Japan)

- P1-7-10** Identification of differentially expressed long non-coding RNAs in the serum of human ovarian cancer patients
Sun-Ae Park
(Department of Obstetrics and Gynecology, Institute of Women's Life Medical Science, Korea)
- P1-7-11** 14-3-3 ζ overexpression is associated with poor prognosis in ovarian cancer
Woong Ju
(Department of Obstetrics and Gynecology, School of Medicine, Ewha Womans University, Korea)
- P1-7-12** Dose dense chemotherapy increases $\gamma\delta$ T cells amount in ovarian cancer
Wan-Chun Huang
(Department of Obstetrics and Gynecology, Mackay Memorial Hospital, Taiwan)
- P1-7-13** Randomized trial of pelvic and lower extremity exercise in patients who underwent pelvic lymph node dissection with lower extremity edema-related symptoms
Myong Cheol Lim
(National Cancer Center, Korea)

Poster Exhibition

Group 8; Ovarian Cancer; Chemotherapy, Molecular Target and Others

- P1-8-1** Intraperitoneal administration of bevacizumab for managing malignant ascites in epithelial ovarian cancer: Experience in a tertiary care hospital of Northern Taiwan
Ting-Xuan Huang
(Department of Obstetrics and Gynecology, Chang Gung Memorial Hospital at Linkou, Taiwan)
- P1-8-2** Safety and efficacy of neoadjuvant chemotherapy with bevacizumab in advanced-stage peritoneal/ovarian cancer patients
Soshi Kusunoki
(Department of Obstetrics and Gynecology, Faculty of Medicine, Juntendo University, Japan)
- P1-8-3** Efficacy and improvement of proteinuria of bevacizumab in patients with platinum-sensitive recurrent ovarian cancer
Shinichi Okame
(Shikoku Cancer Center, Japan)
- P1-8-4** Bevacizumab in ovarian and uterine cervical cancer treatment: 10 years' experience of a single center in Northern Japan
Kei Ihira
(Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Japan)
- P1-8-5** Examination of 30 cases treated with bevacizumab for gynecologic cancer in our hospital
Iemasa Koh
(Hiroshima University, Japan)

- P1-8-6** Safety of using bevacizumab in treating gynecological malignancies: Experience in one medical institute
Shu-Ping Lee
(Department of Obstetrics and Gynecology, National Taiwan University Hospital, Taiwan)
- P1-8-7** The combination therapy of oral cyclophosphamide and bevacizumab for patients with recurrent ovarian cancer, peritoneal cancer and cervical cancer
Mayako Goto
(Department of Obstetrics and Gynecology, Kansai Rosai Hospital, Japan)
- P1-8-8** Immunotherapy of ovarian cancer by targeting cyclophilin B
Wen-Fang Cheng
(National Taiwan University Hospital, Taiwan)
- P1-8-9** Phase 1/2 studies of multiple peptides cocktail vaccine for treatment resistant cervical and ovarian cancer
Satoshi Takekuchi
(Gynecologic Oncology, Iwate Medical University School of Medicine, Japan)
- P1-8-10** Anti-cancer effect of axitinib in ovarian cancer
E Sun Paik
(Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Korea)
- P1-8-11** Hyperthermic intraperitoneal chemotherapy in gynecologic cancer: The experience in one tertiary hospital of Northern Taiwan
Wei-Chun Chen
(Department of Obstetrics and Gynecology, Chang Gung Memorial Hospital at Linkou, Taiwan)

Poster Exhibition

Group 9; Ovarian Cancer; Clinical Characteristics and Outcome

- P1-9-1** Clinical characteristics and prognostic inflection points among long-term survivors of advanced epithelial ovarian cancer
Joo-Hyuk Son
(Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Ajou University School of Medicine, Korea)
- P1-9-2** Clinicopathologic study of 148 mucinous borderline ovarian tumors
Haiyan Zhang
(Obstetrics and Gynecology Hospital of Fudan University, China)
- P1-9-3** Genetic counseling experience of hereditary gynecologic cancer clinic
Min Kyu Kim
(Obstetrics and Gynecology, Sungkyunkwan University of Medicine, Korea)
- P1-9-4** Granulosa cell tumors of ovary: A challenging clinical entity
Veena Jain
(Ludhiana Mediways Hospital, India)

-
- P1-9-5 Hypothesis from observational data: Marriage traits are related to the increase of clear cell carcinoma of ovary**
 Hyo Sook Bae
 (Department of Gynecologic Oncology and Minimally Invasive Surgery, CHA Gangnam Medical Center/CHA University, Korea)
- P1-9-6 Uterine involvement in epithelial ovarian cancer with preoperative and intraoperative tumor-free uterus: The rationale of uterus-conserving staging operation**
 Miseon Kim
 (Department of Obstetrics and Gynecology, Seoul National University Bundang Hospital, Korea)
- P1-9-7 Optimal debulking surgery including systemic pelvic and para-aortic lymphadenectomy: Is it possible during laparoscopic interval debulking surgery after neo-adjuvant chemotherapy in advanced ovarian cancer?**
 Jeong Min Eom
 (Division of Gynecologic Oncology and Gynecologic Minimally Invasive Surgery, Department of Obstetrics and Gynecology, Hanyang University College of Medicine, Korea)
- P1-9-8 Survival outcomes of sex cord-stromal tumors of the ovary**
 Charuwan Tantipalakorn
 (Chiang Mai University, Thailand)
- P1-9-9 Impact of beta blocker medication on survival outcome of ovarian cancer: A nationwide population-based cohort study**
 Min-Hyun Baek
 (Hallym University Sacred Heart Hospital, Korea)
- P1-9-10 Outcomes of non-high grade serous carcinoma after neoadjuvant chemotherapy in advanced-stage ovarian cancer: A single institution retrospective review**
 Young Shin Chung
 (Department of Obstetrics and Gynecology, Institute of Women's Life Medical Science, Yonsei University College of Medicine, Korea)
- P1-9-11 Clinical outcomes of patients with clear cell and endometrioid ovarian cancer arising from endometriosis**
 Ji Hye Kim
 (Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Korea)
- P1-9-12 Postoperative mortality rate and complications after surgery for ovarian cancer: A retrospective study using a national inpatient database in Japan**
 Kimio Wakana
 (Department of Perinatal and Women's Medicine, Tokyo Medical and Dental University, Japan)

Poster Exhibition

Group 10; Ovarian Cancer; Case Report

- P1-10-1** Follicular variant of papillary thyroid carcinoma arising from mature cystic teratoma: A rare case of malignant transformation
Katrina Mae A. Natavio
(Baguio General Hospital and Medical Center, Philippines)
- P1-10-2** Management and therapy carcinosarcoma of ovary: A case report
Teuku Yudhi Iqbal
(Department of Obstetrics and Gynecology, Oncology Division, Syiah Kuala University, Zainoel Abidin General Hospital, Indonesia)
- P1-10-3** A case of adenocarcinoma arising from mature cystic teratoma of the left ovary with metastasis to the breast
Miwa Nakamura
(Department of Obstetrics and Gynecology, Faculty of Life Sciences, Kumamoto University, Japan)
- P1-10-4** A carcinoid tumor arising from a mature cystic teratoma in a 33-year old patient: A case report
Joella B. Gatchalian
(Baguio General Hospital and Medical Center, Philippines)
- P1-10-5** Papillary thyroid carcinoma arising from malignant struma ovarii
Nor Anita Abdullah
(Obstetric & Gynaecology Department, Raja Perempuan Zainab II Hospital, Malaysia)
- P1-10-6** Bilateral cystoid macular edema during a dose-dense paclitaxel and carboplatin chemotherapy in a woman with gynecologic malignancies
Koji Kumagai
(Department of Gynecology, Osaka Railway Hospital, Japan)

Poster Exhibition

Group 11; TR and Others; Basic and Preclinical Research

- P1-11-1** The study of the targeting mechanism between MiR-214 and CTGF/CCN2 in fibrosis of endometriosis in vitro
Mi Xue
(Beijing Obstetrics and Gynecology Hospital, Capital Medical University, China)
- P1-11-2** Oncogenic BRAF promotes global DNA hypomethylation via upregulation of DNA demethylase TET3 level
Ichiro Onoyama
(Kyushu University Hospital, Japan)
- P1-11-3** Elevated level of serum miR-1290 is correlated with high grade serous ovarian cancer and can be a potential biomarker
Masaki Kobayashi
(Osaka University, Japan)

- P1-11-4 The clinical implication of hormone receptor expression in endometrial stromal sarcoma**
Min-Hyun Baek
(Hallym University Sacred Heart Hospital, Korea)
- P1-11-5 Androgen receptor as a prognostic biomarker and therapeutic target in uterine leiomyosarcoma**
Min-Hyun Baek
(Hallym University Sacred Heart Hospital, Korea)
- P1-11-6 Investigation of the immunohistochemical expression of histone deacetylase as a potential therapeutic target and prognostic marker in uterine leiomyosarcoma**
Min-Hyun Baek
(Hallym University Sacred Heart Hospital, Korea)
- P1-11-7 Microsatellite genotyping in the diagnosis of hydatidiform mole: Beyond histology and P57Kip2 staining**
Ruangsak Lertkhachonsuk
(Placental Related Disease Research Unit, Faculty of Medicine, Chulalongkorn University, Thailand)

Poster Exhibition

Group 12; TR and Others; Diagnosis and Prognosis

- P1-12-1 Usefulness of diffusion-weighted MRI (DW-MRI) in the detection of lymph node metastases in patients with gynecological malignancies**
Yoshinori Takeda
(Nara Prefecture General Medical Center, Japan)
- P1-12-2 SPIO method for the diagnosis of pelvic lymph node metastasis**
Kosuke Murakami
(Department of Obstetrics and Gynecology, Kindai University Faculty of Medicine, Japan)
- P1-12-3 Clinical biomarkers for evaluating tumor response during immunotherapy for gynecologic cancers**
Seungmee Lee
(Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Korea)
- P1-12-4 Preoperative value of serum D-dimer and risk factors for deep venous thrombosis in gynecological malignant patients**
Momoe Watanabe
(Department of Obstetrics and Gynecology, Kyorin University School of Medicine, Japan)
- P1-12-5 A nomogram for predicting the risk of lower extremity lymphedema in patients undergoing lymphadenectomy for gynecologic cancers**
Miseon Kim
(Department of Obstetrics and Gynecology, Seoul National University Bundang Hospital, Korea)
- P1-12-6 Prediction model for 30-day morbidity after gynecological malignancy surgery**
Soon-Beom Kang
(Department of Obstetrics and Gynecology, Konkuk University School of Medicine, Korea)

P1-12-7 **Surgicopathological prognostic parameters in uterine leiomyosarcoma: An Asian Gynecologic Oncology Group and Collaborator Study**

Ka Yu Tse

(Queen Mary Hospital, The University of Hong Kong, Hong Kong)

P1-12-8 **Estimation of clinical data by artificial intelligence**

Yasunari Miyagi

(Okayama Ohfuku Clinic, Japan)

[Day 2] December 1 (Friday)

Room 1 (4F Hall)

Morning Lecture 1

Date and Time: December 1 (Friday) 8:00~8:30

Session Room: Room 1 (4F Hall)

Chairperson: Junzo Kigawa

(Department of Obstetrics and Gynecology, Matsue City Hospital, Japan)

ML1 Treatment strategy for young women with ovarian cancer

Kimio Ushijima

(Department of Obstetrics and Gynecology, Kurume University, School of Medicine, Japan)

Symposium 3

Minimally Invasive Surgery

Date and Time: December 1 (Friday) 8:30~10:00

Session Room: Room 1 (4F Hall)

Chairpersons: Young-Tae Kim

(Department of Obstetrics and Gynecology, Yonsei University College of Medicine, Korea)

Chia Yin Nin

(Gleneagles Hospital, Singapore)

SY3-1 The future of robotic surgery for cervical cancer

Fabrice Lécuru

(Department of Gynecologic Oncology, Georges Pompidou European Hospital, Paris Descartes University, School of Medicine, France)

SY3-2 Laparoscopic surgery for endometrial cancer in Japan

Yoshito Terai

(Obstetrics and Gynecology, Osaka Medical College, Japan)

SY3-3 Feasibility of sentinel node navigation surgery in gynecological cancers

Hitoshi Niikura

(Department of Gynecology, Tohoku University Hospital, Japan)

SY3-4 Borderline ovarian tumours and fertility preservation

Chia Yin Nin

(Gleneagles Hospital, Singapore)

December 1 (Fri.)

Invited Lecture 2**P**

Date and Time: December 1 (Friday) 10:20~11:20

Session Room: Room 1 (4F Hall)

Chairpersons: Hee-Sug Ryu

(President-elect, Asian Society of Gynecologic Oncology, Department of OB/GYN,
Ajou University School of Medicine, Korea)

Nobuo Yaegashi

(Tohoku University Hospital, Japan)

IL2-1 Immunobiology and immunotherapy for gynecological cancers

Yutaka Kawakami

(Division of Cellular Signaling, Institute for Advanced Medical Research, Keio University
School of Medicine, Japan)

IL2-2 NRG-GOG Clinical Trials Group

Robert L. Coleman

(Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, The
University of Texas, MD Anderson Cancer Center, USA)

Industrial Lunchtime Seminar 2

Co-sponsored by Kaken Pharmaceutical Co., Ltd.

Date and Time: December 1 (Friday) 11:50~12:40

Session Room: Room 1 (4F Hall)

Chairperson: Kei Kawana

(Department of Obstetrics & Gynecology, Nihon University School of Medicine, Ja-
pan)

ILS2 Can laparoscopy be a treatment of choice for cervical cancer?

Hiroyuki Kanao

(Cancer Institute Hospital, Japan)

Symposium 4

Immune System and Gynecologic Cancers

Date and Time: December 1 (Friday) 13:00~14:20

Session Room: Room 1 (4F Hall)

Chairpersons: Jeong-Won Lee

(Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Korea)

Satoru Kyo

(Department of Obstetrics & Gynecology, Shimane University, Faculty of Medicine, Japan)

SY4-1 PD-1 signal inhibitors for gynecologic cancers: Future perspectives

Junzo Hamanishi

(Department of Obstetrics and Gynecology, Kyoto University, Japan)

SY4-2 Combination of therapeutic HPV DNA vaccine with radiation and immune modulators in HPV associated tumor

Sung-Jong Lee

(Department of Obstetrics and Gynecology, St. Vincent's Hospital, The Catholic University of Korea, Korea)

SY4-3 Immunologic profiles as potential biomarkers for predicting the outcome of ovarian cancer patients

Yu-Li Chen

(Department of Obstetrics and Gynecology, National Taiwan University Hospital, Taiwan)

SY4-4 Reversal of immunosuppression in ovarian cancer microenvironment by targeting NF-κB-IL6/IL8 signal and its clinical application

Takashi Iwata

(Department of Obstetrics and Gynecology, Keio University School of Medicine, Japan)

Symposium 6

Update of Therapeutic Strategy for Ovarian Cancer

P

Date and Time: December 1 (Friday) 14:40~16:10

Session Room: Room 1 (4F Hall)

Chairpersons: Sarikapan Wilailak

(Obstetrics and Gynecology Deputy Dean for Academics & Culture, Thailand)

Tadashi Kimura

(Department of Obstetrics and Gynecology, Osaka University, Japan)

SY6-1 YAP silencing as a new therapeutic strategy for ovarian cancer

Ju-Won Roh

(Department of Obstetrics & Gynecology, Dongguk University, Korea)

SY6-2 Therapeutic strategy for ovarian clear cell carcinoma

Seiji Mabuchi

(Department of Obstetrics and Gynecology, Osaka University, Graduate School of Medicine, Japan)

SY6-3 Selection of antitumor drugs for ovarian cancer based on molecular and pathological subtypes

Noriomi Matsumura

(Department of Obstetrics and Gynecology, Kindai University Faculty of Medicine, Japan)

SY6-4 Pathology of serous tubal intraepithelial carcinoma (STIC) and high grade ovarian serous carcinoma

Steven G. Silverberg

(University of Maryland School of Medicine, USA)

Symposium 7**Management of HBOC in Asia**

Date and Time: December 1 (Friday) 16:30~18:00

Session Room: Room 1 (4F Hall)

Chairpersons: Byoung-Gie Kim

(Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Korea)

Takayuki Enomoto

(Department of Obstetrics and Gynecology, Niigata University, Graduate School of Medical and Dental Sciences, Japan)

SY7-1 Pathogenic germline variants of ovarian, fallopian tube, and peritoneal cancers in Japanese

Akira Hirasawa

(Department of Obstetrics and Gynecology, Keio University School of Medicine, Japan)

SY7-2 The impact of hereditary features on the clinical management of peritoneal, ovarian and fallopian tube cancer

Myong Cheol Lim

(Gynecologic Cancer Branch & Center for Uterine Cancer, National Cancer Center, Korea)

SY7-3 The gBRCAm prevalence study and clinical management of hereditary ovarian cancer in China

Xiaohua Wu

(Department of Gynecologic Oncology, Fudan University Shanghai Cancer Center, China)

SY7-4 Taiwanese patients with ovarian cancer: Prevalence of BRCA1/2 germline and somatic mutations and its clinical implication

Angel Chao

(Department of Obstetrics and Gynecology, Chang Gung Memorial Hospital Linkou Medical Center and Chang Gung University, Taiwan)

Room 2 · 3 (3F 301~304)

Morning Lecture 2

Date and Time: December 1 (Friday) 8:00~8:30

Session Room: Room 2 · 3 (3F 301~304)

Chairperson: Masaki Mandai

(Department of Gynecology and Obstetrics, Kyoto University Graduate School of Medicine, Japan)

ML2 Role of robotic surgery in gynecologic cancer

Suk-Joon Chang

(Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Ajou University School of Medicine, Korea)

Ovarian Cancer 1

Date and Time: December 1 (Friday) 8:30~9:10

Session Room: Room 2 · 3 (3F 301~304)

Chairpersons: Andri Andrijono

(University of Indonesia, Indonesia)

Hiroshi Kobayashi

(Department of Obstetrics and Gynecology, Nara Medical University, Japan)

O5-1 MiR-522 modulates paclitaxel resistance in ovarian cancer cells

Mayuko Miyamoto

(Department of Obstetrics and Gynecology, Osaka University Faculty of Medicine, Japan)

O5-2 Mutation analysis of ctDNA and CTC detection in epithelial ovarian cancer patients

Xiaoxiang Jie

(Obstetrics and Gynecology Hospital, Fudan University, China)

O5-3 Successful reconstitution of high-grade serous ovarian carcinoma in vivo from primary fallopian tube secretory epithelial cells

Kohei Nakamura

(Department of Obstetrics and Gynecology, Shimane University School of Medicine, Japan)

O5-4 Impact of BRCA mutational status on clinical outcome in advanced-stage high-grade serous ovarian cancer

Se Ik Kim

(Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Korea)

Ovarian Cancer 2

Date and Time: December 1 (Friday) 9:10~10:00

Session Room: Room 2 · 3 (3F 301~304)

Chairpersons: Rongyu Zang

(Ovarian Cancer Program, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Zhongshan Hospital, Fudan University, China)

Noriaki Sakuragi

(Department of Gynecology, Otaru General Hospital, Japan)

O6-1 Fertility preservation in patients with ovarian cancer: An updated analysis of SEER data

Kimihiko Sakamoto

(Department of Obstetrics and Gynecology, NTT Medical Center Tokyo, Japan)

O6-2 Effects of fertility-sparing surgery in women of reproductive age with clear-cell carcinoma of the ovary

Masato Yoshihara

(Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Japan)

O6-3 Additional intraperitoneal cisplatin and etoposide to first-line chemotherapy for advanced ovarian cancer (AICE): A randomised, phase 2 trial

Rongyu Zang

(Ovarian Cancer Program, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Zhongshan Hospital, Fudan University, China)

O6-4 Asian perspective on the quality of debulking surgery for advanced-stage ovarian cancer: Results of an international survey

Jisu Seong

(Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Korea)

O6-5 Validation of iMODEL and AGO-score for secondary cytoreductive surgery in recurrent ovarian cancer (clinicaltrials.gov, NCT01611766)

Tingyan Shi

(Ovarian Cancer Program, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Zhongshan Hospital, Fudan University, China)

Educational Lecture

P

Date and Time: December 1 (Friday) 10:20~11:20

Session Room: Room 2・3 (3F 301~304)

Chairpersons: Hidetaka Katabuchi

(Department of Obstetrics and Gynecology, Faculty of Life Sciences, Kumamoto University, Japan)

Takuma Fujii

(Department of Obstetrics and Gynecology, Fujita-Health University, School of Medicine, Japan)

EL-1 Current concepts and controversies in gynecologic pathology

Yoshiki Mikami

(Department of Diagnostic Pathology, Kumamoto University Hospital, Japan)

EL-2 Development of novel HPV therapeutic vaccine: Mucosal immunotherapy of HPV-targeting therapy for treatment of high-grade CIN

Kei Kawana

(Department of Obstetrics & Gynecology, Nihon University School of Medicine, Japan)

Industrial Lunchtime Seminar 3

Co-sponsored by Taiho Pharmaceutical Co., Ltd.

Date and Time: December 1 (Friday) 11:50~12:40

Session Room: Room 2・3 (3F 301~304)

Chairperson: Nobuhiro Takeshima

(Department of Obstetrics and Gynecology, The Cancer Institute Hospital of JFCR, Japan)

ILS3 Antiemetic therapy in gynecologic cancer: Winning the battle against chemotherapy-induced nausea and vomiting (CINV)

Masakazu Abe

(Division of Gynecologic Oncology, Shizuoka Cancer Center, Japan)

December 1 (Fri.)

Symposium 5

Cervical Cancer Screening in Asia

Co-sponsored by Hologic, Inc.

Date and Time: December 1 (Friday) 13:00~14:20

Session Room: Room 2 · 3 (3F 301~304)

Chairpersons: Hextan Ngan Yuen Sheung

(Department of Obstetrics and Gynaecology, the University of Hong Kong, Queen Mary Hospital, Hong Kong)

Suresh Kumarasamy

(Penang Medical College, Malaysia)

SY5-1 Cervical cancer screening in Hong Kong

Hextan Ngan Yuen Sheung

(Department of Obstetrics and Gynaecology, the University of Hong Kong, Queen Mary Hospital, Hong Kong)

SY5-2 Cervical cancer screening in Asia

Neerja Bhatla

(Department of Obstetrics & Gynaecology, All India Institute of Medical Sciences, India)

SY5-3 Cervical cancer screening in Malaysia

Suresh Kumarasamy

(Penang Medical College, Malaysia)

SY5-4 Cervical cancer screening in Japan and its directed approach

Masatsugu Ueda

(Cytopathology and Gynecology, Osaka Center for Cancer and Cardiovascular Disease Prevention, Japan)

Cervical Cancer 1

Date and Time: December 1 (Friday) 14:40~15:20

Session Room: Room 2 · 3 (3F 301~304)

Chairpersons: Jae-Kwan Lee

(Department of Obstetrics and Gynecology, Korea University Guro Hospital, Korea)

Yoh Watanabe

(Department of Obstetrics and Gynecology, Tohoku Medical and Pharmaceutical University, Japan)

O7-1 Methyltransferase G9A is a marker of aggressive cervical cancer and suppresses tumor cell senescence

Chinjui Wu

(Department of Obstetrics and Gynecology, Taoyuan General Hospital, Taiwan)

-
-
- O7-2** **Cost-effectiveness analysis of AS04-adjuvanted human papillomavirus 16/18 vaccine in adolescent girls in Taiwan**
Christa Lee
(GSK, Singapore)
- O7-3** **Suggesting ideal strategy of cervical cancer screening in Japan: First report of the Fukui Cervical Cancer Screening Study**
Tetsuji Kurokawa
(University of Fukui, Japan)
- O7-4** **Clinical outcome of high-grade cervical intraepithelial neoplasia during pregnancy: A 10-year experience**
Seon Ah Kim
(Department of Obstetrics and Gynecology, Cheil General Hospital and Women's Healthcare Center, Dankook University College of Medicine, Korea)

Cervical Cancer 2

Date and Time: December 1 (Friday) 15:20~16:10

Session Room: Room 2 · 3 (3F 301~304)

Chairpersons: David Tan

(National University Cancer Institute, Singapore)

Nobuhiro Takeshima

(Department of Obstetrics and Gynecology, The Cancer Institute Hospital of JFRCR, Japan)

- O8-1** **International surgical training in gynecologic oncology using a soft cadaver**
Tomoyasu Kato
(Department of GYN, National Cancer Center Hospital, Japan)
- O8-2** **Predicting factors for resumption of spontaneous voiding following nerve-sparing radical hysterectomy**
Chalaithorn Nantasupha
(Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Faculty of Medicine, Chiang Mai University, Thailand)
- O8-3** **Oncological outcomes of an improved NSRH technique in 177 cervical cancer patients**
Sheng Yin
(Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Zhongshan Hospital, Fudan University, China)
- O8-4** **Multi-institutional observational study of prophylactic extended-field concurrent chemoradiotherapy using weekly cisplatin for patients with locally advanced cervical cancer in East and Southeast Asia**
Noriyuki Okonogi
(Hospital, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Japan)

O8-5 Multi-institutional clinical studies of radiotherapy for cervical cancer among Asian countries under the framework of Forum for Nuclear Cooperation in Asia (FNCA)

Masaru Wakatsuki

(Department of Radiology, Jichi Medical University, Japan)

**Symposium 8
Fertility-Sparing Strategy**

Date and Time: December 1 (Friday) 16:30~18:00

Session Room: Room 2・3 (3F 301~304)

Chairpersons: Jianliu Wang

(Department of Obstetrics and Gynecology, Peking University People's Hospital, China)

Nao Suzuki

(Department of Obstetrics and Gynecology, St. Marianna University, School of Medicine, Japan)

SY8-1 Fertility sparing surgery of trachelectomy for cervical cancer

Hiroaki Kobayashi

(Department of Obstetrics and Gynecology, Faculty of Medicine, Kagoshima University, Japan)

SY8-2 Outcomes of fertility-preserving high-dose progestin therapy for young patients with endometrial cancer

Nobuyuki Susumu

(Department of Obstetrics and Gynecology, International University of Health and Welfare, Japan)

SY8-3 Fertility-sparing strategy for gynecologic cancers

Jeong-Yeol Park

(Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center, Korea)

SY8-4 Fertility preservation of endometrial cancer in China

Jianliu Wang

(Department of Obstetrics and Gynecology, Peking University People's Hospital, China)

SY8-5 A non-randomized confirmatory study regarding selection of fertility-sparing surgery for patients with epithelial ovarian cancer: Japan Clinical Oncology Group Study JCOG1203

Toyomi Satoh

(Department of Obstetrics and Gynecology, Faculty of Medicine, University of Tsukuba, Japan)

3F 311

FIGO Session

Date and Time: December 1 (Friday) 8:30~10:00

Session Room: 3F 311

FIGO Staging Revision: The Way Forward

Neerja Bhatla

(Department of Obstetrics & Gynaecology, All India Institute of Medical Sciences, India)

Poster Exhibition

Date and Time: December 1 (Friday) 10:00~18:00

Session Room: Poster Exhibition (3F · 4F Foyer)

Poster Exhibition

Group 13; Cervical Cancer; Basic and Preclinical Research

- P2-1-1** Decreased level of fructose-1,6-bisphosphatase-1 promotes carcinogenesis and chemoresistance in cervical cancer
Haoran Li
(Fudan University Shanghai Cancer Center, China)
- P2-1-2** Propofol enhances the cisplatin-induced apoptosis on cervical cancer cells via EGFR/JAK2/STAT3 pathway
Xi Cheng
(Fudan University Shanghai Cancer Center, China)
- P2-1-3** Expression of Nod1 and Nod2 during progression of human cervical neoplasia and their correlation with P16INK4a expression
Tae-Hyun Kim
(Department of Obstetrics and Gynecology, College of Medicine, Konyang University, Korea)
- P2-1-4** Hypermethylation of single-minded homolog 1 (SIM1) gene as a potential biomarker for cervical cancer
Seung Cheol Kim
(Department of Obstetrics and Gynecology, School of Medicine, Ewha Womans University, Korea)
- P2-1-5** Cytokines profiles of cervical mucosa of patients with cervical high-risk human papillomavirus infection
Pengpeng Qu
(Tianjin Central Hospital of Obstetrics and Gynecology, China)
- P2-1-6** The diagnostic performance of cyclinA1 promoter methylation in self-sampling test
Malika Kengsakul
(Department of Obstetrics and Gynecology, Faculty of Medicine, Chulalongkorn Memorial Hospital, Chulalongkorn University, Thailand)

Poster Exhibition

Group 14; Cervical Cancer; Clinical Characteristics, HPV, Screening and CIN

- P2-2-1** Cervical cancer patients profile at Dr. Wahidin Sudirohusodo Hospital, Makassar, Indonesia in 2016
Ayu Angelina
(Obstetrics and Gynecology Department, Faculty of Medicine, Hasanuddin University, Indonesia)

-
- P2-2-2** **Influence of aging on the treatment and prognosis of patients with cervical cancer**
Kumi Shimamoto
(Kyushu-Cancer Center, Japan)
- P2-2-3** **Age-specific change in the incidence of cervical cancer in Japanese women: Analysis of correlation with the risk factors by birth cohort**
Atsuko Sakakibara
(Department of Preventive Medicine, Medical Research Institute, Kitano Hospital, Japan)
- P2-2-4** **Accurate interpretation of cervical smears: audits are important**
Neelkamal Kapoor
(Department of Pathology and Lab Medicine AIIMS, India)
- P2-2-5** **Human papillomavirus genotypes identified in high-grade CIN and invasive cervical cancer in Japanese women**
Jinichi Sakamoto
(Kanazawa Medical University, Japan)
- P2-2-6** **The incidence of HSIL and worse lesion in women with high-risk human papilloma virus and normal cervical cytology: A retrospective analysis of 1858 cases with age-stratified and HPV genotype**
Liyang Gu
(Department of Gynecology and Obstetrics, Renji Hospital, Shanghai JiaoTong University School of Medicine, China)
- P2-2-7** **Prognostic value of pre-treatment human papilloma virus DNA status in cervical cancer**
Gun Oh Chong
(Kyungpook National University Chilgok Hospital, Gynecologic Cancer Center, Korea)
- P2-2-8** **Attitudes regarding HPV vaccinations of children among mothers with adolescent daughters in Korea**
Kyong-No Lee
(Department of Obstetrics & Gynecology, Kangnam Sacred Heart Hospital, The Hallym University of Korea, Korea)
- P2-2-9** **Effectiveness on high-grade cervical abnormalities and long-term safety of the quadrivalent HPV vaccine in Japanese women**
Etsuko Miyagi
(Yokohama City University School of Medicine, Japan)
- P2-2-10** **The status of screening management in Japanese local governments using co-testing cytology/ HPV cervical cancer screening methods**
Kanao Kono
(Screening Assessment and Management Division, Center for Public Health Sciences, National Cancer Center, Japan)
- P2-2-11** **Cervical cancer screening program based on visual inspection with acetic acid (VIA) method in Jakarta, Indonesia, 2004-2010**
Gatot Purwoto
(Oncology Gynecology Division, Obstetrics and Gynecology Department, Faculty of Medicine, Universitas Indonesia, Indonesia)

P2-2-12 Challenges and opportunities for selected population based cervical cancer screening programs in United States (US) and Asia

Cheng-I Liao

(Department of Obstetrics & Gynecology, Kaohsiung Veterans General Hospital, Taiwan)

P2-2-13 Prevalence of cervical intraepithelial neoplasia (CIN) 2+ in patients with atypical squamous cells of undetermined significance (ASC-US) in Bangkok and rural Pathum Thani province, Thailand

Nuttavut Kantathavorn

(Gynecologic Oncology Division, Woman Health Center, Chulabhorn Hospital, HRH Princess Chulabhorn College of Medical Science, Chulabhorn Royal Academy, Thailand)

P2-2-14 Prevalence of high-grade cervical lesion (CIN 2+) in women with low grade squamous intraepithelial lesion (LSIL) cytology in Thailand

Asama Vanichtantikul

(Gynecologic Oncology Division, Woman Health Center, Chulabhorn Hospital, HRH Princess Chulabhorn College of Medical Science, Chulabhorn Royal Academy, Thailand)

Poster Exhibition

Group 15; Endometrial Cancer; Chemotherapy, MPA and Others

P2-3-1 Survival impact of four versus six cycles of adjuvant chemotherapy in endometrial carcinoma

Michinori Mayama

(Department of Obstetrics and Gynecology, Oji General Hospital, Japan)

P2-3-2 Adjuvant docetaxel and carboplatin chemotherapy for patients with high-intermediate and high-risk endometrial cancer

Wataru Kudaka

(University of the Ryukyus Hospital, Japan)

P2-3-3 Adjuvant therapy for improving survival outcomes in women with uterine-confined endometrial cancer of endometrioid grade 3, serous papillary and clear cell histology: A multicenter study

Miseon Kim

(Department of Obstetrics and Gynecology, Seoul National University Bundang Hospital, Korea)

P2-3-4 Conservative management of endometrial carcinoma

Raissa Liem

(Department of Obstetrics and Gynecology, Faculty of Medicine, Universitas Indonesia, Indonesia)

Poster Exhibition

Group 16; Endometrial Cancer; Clinical Characteristics and Outcome

P2-4-1 Trends in uterine cancer incidence in the US and asian countries: A population analysis of 576,558 of women

Cheng-I Liao

(Department of Obstetrics & Gynecology, Kaohsiung Veterans General Hospital, Taiwan)

- P2-4-2 Clinical analysis of stage I, high risk endometrial cancer: A Taiwanese Gynecology Oncology Group (TGOG 2009) retrospective cohort study**
Fu-Shing Liu
(Department of Obstetrics and Gynecology, Show Chwan Memorial Hospital, Taiwan)
- P2-4-3 Uterine cancer treatment in Nepal**
Pabitra Maharjan
(Civil Service Hospital, Nepal)
- P2-4-4 Therapeutic effect of systemic para-aortic and pelvic lymphadenectomy for FIGO stage IIIC endometrioid adenocarcinoma of the uterine body**
Kenta Takahashi
(Department of Gynecology, National Cancer Center Hospital, Japan)
- P2-4-5 The safety and the efficacy of laparoscopic surgery for endometrial cancer: A single institutional preliminary study**
Seiji Mabuchi
(Department of Gynecology, Osaka University Graduate School of Medicine, Japan)
- P2-4-6 A comparison of short-term outcomes between laparotomy and laparoscopic surgery for early-stage endometrial cancer**
Emiko Niino
(Department of Obstetrics and Gynecology, Nara Medical University, Japan)
- P2-4-7 Prognostic analysis and the discussion on the adjuvant therapy of intermediate risk endometrial carcinoma**
Wenjuan Tian
(Department of Gynecologic Oncology, Fudan University Cancer Center, China)
- P2-4-8 Retrospective analysis of 14 leiomyosarcoma cases treated in our institution**
Keisuke Kodama
(Department of Obstetrics and Gynecology, Graduate School of Medical Sciences, Kyushu University, Japan)
- P2-4-9 Risk factors for unsuccessful office based endometrial biopsy: A comparative study of pipelle and diagnostic dilation and curettage (D&C)**
Bingying Xie
(Obstetrics and Gynecology Hospital of Fudan University, China)

Poster Exhibition

Group 17; Endometrial Cancer; Case Report

- P2-5-1 Uterine preservation in a young patient with adenosarcoma of the uterus: Case report and review of literature**
Charissa Goh
(KK Women's & Children's Hospital, Singapore)
- P2-5-2 Second primary uterine carcinosarcoma after concurrent chemoradiotherapy for cervical cancer**
Akihiko Wakayama
(University of the Ryukyus, Japan)

P2-5-3 Two cases of uterine sarcoma well-controlled with eribulin

Etsuko Fujimoto

(Department of Gynecologic Oncology, National Hospital Organization Shikoku Cancer Center, Japan)

P2-5-4 Uterine carcinosarcoma with alpha-fetoprotein producing hepatoid component: A case report and literature review

Joshua JX Li

(Department of Anatomical and Cellular Pathology, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong)

P2-5-5 MLH1 promoter hypermethylation cannot rule out lynch syndrome-associated endometrial carcinoma with MLH1 germline mutation

Takanori Yokoyama

(Shikoku Cancer Center, Japan)

Poster Exhibition**Group 18; Ovarian Cancer; Basic Research****P2-6-1 Follicle-stimulating hormone receptor-targeted glycolysis suppressing and its therapeutic effect on ovarian cancer**

Meng Zhang

(Obstetrics and Gynecology Hospital of Fudan University, China)

P2-6-2 C-myc mediated FBP1 regulates cell metastasis and metabolism by suppressing STAT3 in ovarian cancer

Xi Cheng

(Fudan University Shanghai Cancer Center, China)

P2-6-3 Galectin-1 induces invasion and the epithelial-mesenchymal transition in human ovarian cancer cells via activation of the MAPK JNK/p38 signaling pathway

Jie Zhu

(Obstetrics and Gynecology Hospital of Fudan University, China)

P2-6-4 REV3L, a promising target in regulating chemosensitivity and stem-ness of ovarian cancer cells

Mengjiao Li

(Fudan University Shanghai Cancer Center, China)

P2-6-5 Exosomes derived from hypoxic epithelial ovarian cancer cells deliver microRNAs to macrophages to elicit a tumor-promoted phenotype

Xipeng Wang

(Xinhua Hospital, Affiliated with Shanghai Jiao Tong University, School of Medicine, China)

P2-6-6 Genomic landscape of ovarian clear cell carcinoma via next generation sequencing

Maria Lee

(Seoul National University Hospital, Korea)

P2-6-7 Exosomes released from TAMs transfer microRNAs inducing Treg/Th17 imbalance in EOC

Xipeang Wang

(Xinhua Hospital, Affiliated with Shanghai Jiao Tong University, School of Medicine, China)

- P2-6-8** Downregulation of miR-503 contributes to the development of drug resistance in ovarian cancer by targeting PI3K p85
Di Wu
(Department of Gynecologic Oncology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, China)
- P2-6-9** The role of peritoneal mesothelial cells on neovascularization in peritoneal dissemination of ovarian cancer
Kayo Fujikake
(Department of Obstetrics and Gynecology, Graduate School of Medicine, Nagoya University, Japan)
- P2-6-10** Bufalin inhibits cellular glycolysis-induced cell growth and proliferation through repression of the ITGB2/FAK pathway in ovarian cancer cells
Xi Cheng
(Fudan University Shanghai Cancer Center, China)
- P2-6-11** Retro-inverso follicle-stimulating hormone peptide-mediated polyethylenimine for ovarian cancer gene therapy
Mengyu Zhang
(Obstetrics and Gynecology Hospital of Fudan University, China)
- P2-6-12** MDM2 inhibitor DS-3032b and mTOR inhibitor everolimus exerts antitumor effect in ovarian and renal cell clear cell carcinomas
Yoshiko Kawata
(Department of Obstetrics and Gynecology, Faculty of Medicine, The University of Tokyo, Japan)
- P2-6-13** Complementing cisplatin: Metformin suppresses epithelial ovarian cancer proliferation, migration and invasion in vitro and in vivo
Ya Zheng
(Department of Gynecology, Obstetrics and Gynecology Hospital of Fudan University, China)

Poster Exhibition

Group 19; Ovarian Cancer; Diagnosis and Prognosis

- P2-7-1** The clinical utility of ROMA in Chinese patients-experience from a medical center in Taiwan
Wen-Chieh Huang
(Kaohsiung Veterans General Hospital, Taiwan)
- P2-7-2** A novel algorithm for the treatment strategy for advanced epithelial ovarian cancer: Consecutive imaging, frailty assessment, and diagnostic laparoscopy
Kyung Jin Eoh
(Department of Obstetrics and Gynecology, Institute of Women's Medical Life Science, Yonsei University College of Medicine, Korea)
- P2-7-3** Machine learning-guided staging in patients with epithelial ovarian cancer
E Sun Paik
(Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Korea)

-
- P2-7-4 Differences in correlation of progression-free survival and overall survival by clinical variables in epithelial ovarian cancer**
E Sun Paik
(Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Korea)
- P2-7-5 Predictors of suboptimal cytoreduction in patients undergoing primary surgery for advanced ovarian carcinoma**
Bushra Khan
(Aga Khan University Hospital, Pakistan)
- P2-7-6 Effect of BMI, CA 125, hemoglobin, physical performance and ovarian carcinoma stages on operated patient comorbidity**
Christofer JH Ladja
(Obstetric & Gynecology Departement, Faculty of Medicine, Hasanuddin University, Indonesia)
- P2-7-7 The relationship between CA-125, ultrasonography examination and risk indications and the stage in ovarian cancer**
Eddy Wardhana
(Obstetric & Gynecology Departement, Faculty of Medicine, Hasanuddin University, Indonesia)
- P2-7-8 Value of CA125 rise as an indicator for imaging for detection of recurrence**
Pesona Lucksom
(Tata Medical Center, India)
- P2-7-9 Comparison serum HE4 with CA125 for detecting recurrence in ovarian cancer**
Nara Lee
(Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Korea)
- P2-7-10 Accuracy of hE4 and VEGF-A protein in the diagnosis of epithelial ovarian carcinoma**
Namira Bachtiar
(Obstetric and Gynecology Departement, Faculty of Medicine, Hasanuddin University, Indonesia)
- P2-7-11 Preoperative plasma D-dimer level is a useful prognostic marker in ovarian cancer**
Yuki Yamada
(Department of Obstetrics and Gynecology, Nara Medical University, Japan)
- P2-7-12 Fn14 expression predicts metastasis and prognosis in patients with epithelial ovarian cancer**
An, Yue Wu
(Department of Obstetrics and Gynecology, Ren Ji Hospital, School of Medicine, Shanghai JiaoTong University, China)
- P2-7-13 Hormone receptor expression of primary epithelial ovarian neoplasms and their prognostic implications, A preliminary study**
Arpitha Anantha Raju
(Kidwai Memorial Institute of Oncology, India)

-
-
- P2-7-14** Differentiation between stage I ovarian cancer and borderline epithelial ovarian tumor by apparent diffusion coefficient value
Tadaharu Nakasone
(Department of Obstetrics and Gynecology, Graduate School of Medicine, University of the Ryukyus, Japan)
- P2-7-15** Evaluation of 18F-FDG PET/CT imaging to detect lymph node metastases in patients with epithelial ovarian cancer
Takuto Matsuura
(Department of Obstetrics and Gynecology, Kameda Medical Center, Japan)
- P2-7-16** Diagnostic value of integrated 18F-fluoro-2-deoxyglucose positron emission tomography/computed tomography in recurrent epithelial ovarian cancer: Accuracy of patient selection for secondary cytoreduction in 134 patients
Young-Jae Lee
(Asan Medical Center, Korea)
- P2-7-17** SUVmax on PET/CT and the prognosis of ovarian clear cell carcinomas
Kaori Kiuchi
(Department of Obstetrics and Gynecology, Dokkyo Medical University, Japan)

Poster Exhibition

Group 20; TR and Others; Clinical Management

- P2-8-1** Impact of peritoneal closure and retroperitoneal drainage on patients who underwent laparotomic retroperitoneal lymph node dissection
Hui-Hua Chen
(Department of Obstetrics and Gynecology, Far Eastern Memorial Hospital, Taiwan)
- P2-8-2** Prevention of postoperative adhesion by a sodium hyaluronate-based bioresorbable membrane in advanced ovarian cancer
Ayako Nozaki
(Department of Obstetrics and Gynecology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Japan)
- P2-8-3** Impact of morcellation on recurrence of patients with cellular leiomyoma after laparoscopic myomectomy
Jeong Min Eom
(Division of Gynecologic Oncology and Gynecologic Minimally Invasive Surgery, Department of Obstetrics and Gynecology, Hanyang University College of Medicine, Korea)
- P2-8-4** Management of massive bleeding in term primary abdominal pregnancy with abdominal packing and intra placental methotrexate injection
David, Eka Prasetya
(OBGYN Indonesian University, Indonesia)
- P2-8-5** Infusion hypersensitivity reactions occurring beyond the third cycle of paclitaxel in gynecologic cancer
Rachadapan Chaitosa
(Gynecology Department, Ramathibodi Hospital, Thailand)

- P2-8-6** **Peripheral neurotoxicity in gynecologic oncology patients who received paclitaxel**
 Prapaporn Suprasert
 (Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Faculty of Medicine, Chiang Mai University, Thailand)
- P2-8-7** **Examination of the efficacy of combination therapy with DOAC and fondaparinux in gynecology patients with venous thromboembolism**
 Noriyuki Yokomichi
 (Department of Obstetrics & Gynecology, St. Marianna University School of Medicine, Japan)
- P2-8-8** **Nutritional status changes of gynecologic cancer patients before and after treatment in Gynecologic Ward Dr. Cipto Mangunkusumo Hospital, Jakarta**
 Hariyono Winarto
 (Oncology Gynecology Division, Obstetrics and Gynecology Department, Faculty of Medicine, Universitas Indonesia, Indonesia)
- P2-8-9** **Surgical anatomy of gynecologic malignancies by cadaveric study**
 Satoshi Kawai
 (Department of Obstetrics and Gynecology, Fujita-Health University, School of Medicine, Japan)

Poster Exhibition

Group 21; TR and Others; Rare Tumor

- P2-9-1** **Clinical characteristics and oncological outcomes of gynecologic cancer during pregnancy: 10-years' experience and literature review**
 Achjima Tankul
 (Gynecologic Oncology Division, Department of Obstetrics & Gynecology, Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand)
- P2-9-2** **Brain metastases of gestational choriocarcinoma: Retrospective analysis of seven cases**
 Hirokazu Usui
 (Department of Reproductive Medicine, Chiba University Graduate School of Medicine, Japan)
- P2-9-3** **Primary retroperitoneal squamous cell carcinoma: A case report with review of the literature**
 Yu Matsuzaka
 (Department of Obstetrics and Gynecology, National Hospital Organization Kyoto Medical Center, Japan)
- P2-9-4** **Brain metastasis in young adult patients with gynecologic cancer: 2 cases report**
 Kazuto Tasaki
 (St. Mary's Hospital, Japan)
- P2-9-5** **A rare case report of adenocarcinoma arising from mature cystic teratoma of ovary**
 Tofan Widya Utami
 (Department of Obstetrics and Gynecology, Oncology-Gynecology Division, Faculty of Medicine, University of Indonesia, Cipto Mangunkusumo Hospital, Indonesia)

-
-
- P2-9-6** The considering of the image evaluation of gastrointestinal stromal tumor (GIST) mimicking gynecological tumors
Shoma Koga
(Japanese Red Cross Kumamoto Hospital, Japan)
- P2-9-7** Malignant psoas syndrome in gynecological malignancy: Three case reports and review of the literature
Shiro Takamatsu
(Department of Gynecology and Obstetrics, Kindai University Faculty of Medicine, Japan)
- P2-9-8** Outcome of gestational trophoblastic neoplasia: Experience from a tertiary referral hospital in Indonesia
Andri
(Department of Obstetrics and Gynaecology, University of Indonesia Faculty of Medicine, Indonesia)

Poster Exhibition

Group 22; TR and Others; Case Report

- P2-10-1** A case of atypical polypoid adenomyoma: The findings of follow-up 18F-FDG PET-CT after trans-cervical resection
Makoto Akiyama
(Department of Obstetrics and Gynecology, Matsushita Memorial Hospital, Japan)
- P2-10-2** A rare case of synchronous tumors: clear cell adenocarcinoma of cervix and borderline mucinous ovarian tumor
Putri Addina
(Department of Obstetrics and Gynecology, Faculty of Medicine, Universitas Indonesia, Indonesia)
- P2-10-3** Serous carcinoma of the fallopian tube with squamous differentiation: A case report and a literature review
Jong Hee Nam
(Department of Pathology, Chonnam National University Medical School, Korea)
- P2-10-4** Primary omental synovial sarcoma mimicking ovarian cancer
Naoyuki Iwahashi
(Department of Obstetrics and Gynecology, Wakayama Medical University, Japan)
- P2-10-5** A case of peritoneal mesothelioma preoperatively suspected to be ovarian cancer
Satoshi Shibasaki
(Department of Obstetrics and Gynecology, Faculty of Life Sciences, Kumamoto University, Japan)
- P2-10-6** Malignant perivascular epithelioid cell tumor (PEComa) of the uterus with rapid recurrence: A case report and mini-review of the literature
San-Nung Chen
(Department of Obstetrics and Gynecology, Kaohsiung Veterans General Hospital, Taiwan)

-
- P2-10-7** **A case with the successful outcome of pregnancy following in vitro maturation and fertilization of oocytes extracted from the removed ovary with a serous borderline tumor**
 Shotaro Higuchi
 (Department of Obstetrics and Gynecology, Shinshu University School of Medicine, Japan)
- P2-10-8** **A case report of gestational choriocarcinoma complicated by infective endocarditis during chemotherapy**
 Yutaka Nagai
 (Department of Obstetrics and Gynecology, Okinawa Prefectural Nanbu Medical Center & Children's Medical Center, Japan)
- P2-10-9** **Lung metastatic choriocarcinoma successfully treated with carboplatin and paclitaxel in conservative treatment: A case report**
 Prima Ovalina
 (Department of Obstetrics and Gynaecology, Faculty of Medicine Universitas Indonesia, Indonesia)
- P2-10-10** **Choriocarcinoma with uterine perforation presenting as haemoperitoneum and anemic condition: A rare case report**
 Donny Ataufika
 (Department of Obstetrics and Gynecology, Syiah Kuala University, Zainoel Abidin General Hospital, Indonesia)
- P2-10-11** **Primary cervical choriocarcinoma with germ cell tumor: A case report with literature review**
 Pan Lu
 (Department of Gynecologic Oncology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, China)
- P2-10-12** **Short tandem repeat analysis for confirmation of uterine non-gestational choriocarcinoma in a postmenopausal Taiwanese woman case report**
 Chin-Jui Wu
 (Department of Obstetrics and Gynecology, Taoyuan General Hospital, Taiwan)
- P2-10-13** **A case of vaginal malignant tumor resected by modified vaginal simple hysterectomy**
 Naomi Iwasa
 (National Hospital Organization Saitama National Hospital, Japan)
- P2-10-14** **A case of recurrent pseudomyxoma peritonei treated with bevacizumab**
 Nobuaki Kosaka
 (Department of Obstetrics and Gynecology, Dokkyo Medical University, Japan)
- P2-10-15** **Vulvar cancer in pregnancy: A case report**
 Andri
 (Gynecologic Oncology Division, Department of Obstetrics and Gynecology, Faculty of Medicine University of Indonesia, Cipto Mangunkusumo General Hospital, Indonesia)

[Day 3] December 2 (Saturday)

Room 1 (4F Hall)

GCIG Symposium

An Introduction to the Gynecologic Cancer InterGroup

Date and Time: December 2 (Saturday) 8:00~11:00

Session Room: Room 1 (4F Hall)

Chairperson: Jonathan Berek

(GCIG Director (COGI), Chair of GCIG Education Working Group, GCIG Liaison to FIGO & IGCS)

Overview

Andres Poveda

(GCIG Chair, Past Chair of GEICO)

Operations

Katherine Bennett

(GCIG Operations & Executive Officer)

Ovarian Primary Rx Controversies

Keiichi Fujiwara

(GCIG Chair Elect, GCIG Director (GOTIC))

Ovarian Trials

Mansoor Mirza

(GCIG Director (NSGO); co-Chair GCIG Phase II Committee)

Endometrial & Rare Tumors Trials

Jae-Weon Kim

(GCIG Director (KGOG))

Cervical Trials & CCRN

Jonathan Berek

(GCIG Director (COGI), Chair of GCIG Education Working Group, GCIG Liaison to FIGO & IGCS)

Panel Discussion

Industrial Lunchtime Seminar 4

Co-sponsored by AstraZeneca

Date and Time: December 2 (Saturday) 11:20~12:10

Session Room: Room 1 (4F Hall)

Chairperson: Junzo Kigawa

(Department of Obstetrics and Gynecology, Matsue City Hospital, Japan)

ILS4 Targeted and individualized therapy for advanced ovarian cancer

Robert L. Coleman

(Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, The University of Texas, MD Anderson Cancer Center, USA)

Invited Lecture 3

P

Date and Time: December 2 (Saturday) 12:30~13:30

Session Room: Room 1 (4F Hall)

Chairpersons: Soon-Beom Kang

(Department of Obstetrics & Gynecology, Women's Gynecology Cancer Center of Konkuk University Medical Center, Korea)

Toru Sugiyama

(Department of Obstetrics and Gynecology of the Iwate Medical University, School of Medicine, Japan)

IL3-1 Update on clear cell carcinoma of ovary

Aikou Okamoto

(Department of Obstetrics and Gynecology, The Jikei University School of Medicine, Japan)

IL3-2 Role of PARP inhibitors in ovarian cancer

Mansoor R Mirza

(Department of Oncology, Rigshospitalet Copenhagen University Hospital, Denmark)

Room 2 (3F 301 • 302)

Symposium 9

Update of Endometrial Cancer

Date and Time: December 2 (Saturday) 9:30~11:00

Session Room: Room 2 (3F 301 • 302)

Chairpersons: Peng-Hui Wang

(Department of Obstetrics and Gynecology, Taipei Veterans General Hospital and National Yang-Ming University School of Medicine, Taiwan; President of the Taiwan Association of Gynecology, Taiwan)

Toshiaki Saito

(Gynecology Service, National Kyushu Cancer Center, Japan)

SY9-1 Endometrial cancers: An Indian experience

Abraham Peedicayil

(Department of Gynaecologic Oncology, CMC Hospital, India)

SY9-2 Immunotherapy in endometrial cancer

Jung-Yun Lee

(Department of Obstetrics and Gynecology, Yonsei University, Korea)

SY9-3 Management of lymph nodes in endometrial cancer

Yukiharu Todo

(Division of Gynecologic Oncology, Hokkaido Cancer Center, Japan)

SY9-4 The recent novel findings in adjuvant chemotherapy for endometrial cancer

Hiroyuki Nomura

(Department of Obstetrics and Gynecology, Keio University School of Medicine, Japan)

Industrial Lunchtime Seminar 5

Co-sponsored by Chugai Pharmaceutical Co., Ltd.

Date and Time: December 2 (Saturday) 11:20~12:10

Session Room: Room 2 (3F 301 • 302)

Chairperson: Young-Tak Kim

(University of Ulsan College of Medicine, ASAN Medical Center, Korea)

ILS5 The role of bevacizumab in cervical and ovarian cancers

Efren J. Domingo

(University of the Philippines, Philippines)

Invited Lecture 4

P

Date and Time: December 2 (Saturday) 12:30~13:30

Session Room: Room 2 (3F 301 · 302)

Chairpersons: Seung Cheol Kim

(Ewha Womans University Cancer Center for Women, Korea)

Daisuke Aoki

(Department of Obstetrics and Gynecology, Keio University School of Medicine, Japan)

IL4-1 The biology of ovarian cancer

Ernst Lengyel

(Department of Obstetrics and Gynecology/Section of Gynecologic Oncology, The University of Chicago, USA)

IL4-2 Sentinel navigation surgery for cervical cancer

Fabrice Lécuru

(Department of Gynecologic Oncology, Georges Pompidou European Hospital, Paris Descartes University, School of Medicine, France)

Room 3 (3F 303 · 304)

JGO offers Selected Pre-submission Review

Date and Time: December 2 (Saturday) 7:45~8:45

Session Room: Room 3 (3F 303 · 304)

Chairpersons: Chulmin Lee

(Inje University, Korea)

Jianliu Wang

(Peking University, China)

Speaker:

Kyung-Jin Min

(Korea University, Korea)

Sung-Jong Lee

(Catholic University of Korea, Korea)

Jeong-Yeol Park

(University of Ulsan, Korea)

Seung-Hyuk Shim

(Konkuk University, Korea)

Dong-Hoon Suh

(Seoul National University, Korea)

Tianhui Chen

(Zhejiang Academy of Medical Sciences, China)

Young Doctors' Session 3

Date and Time: December 2 (Saturday) 9:45~10:45

Session Room: Room 3 (3F 303 · 304)

Chairpersons: Hiroaki Kajiyama

(Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Japan)

Masahide Ohmichi

(Department of Obstetrics and Gynecology, Osaka Medical College, Japan)

- YD3-1 The correlation between squamous cell abnormalities by liquid based cytology and histopathology**
Wilasinee Areeruk
(Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thailand)
- YD3-2 Importance of advocacy lectures on women's awareness and attitude on cervical cancer screening and HPV vaccination: A pilot observational study**
Jimmy A Billod
(Baguio General Hospital and Medical Center, Philippines)
- YD3-3 Loop electrosurgical excision procedure for cervical intraepithelial neoplasia is effective for cervical cancer prevention**
Jitendra Pariyar
(Civil Service Hospital, Nepal)
- YD3-4 Can adjuvant treatment be avoided in women treated surgically for early stage cervical cancer? Audit report from a tertiary center**
Swati Mittal
(Tata Medical Center, India)
- YD3-5 Long follow-up of patients with intermediate to high risk cervical cancer treated with postoperative radiation therapy**
Yuma Iwai
(Department of Radiology, Chiba University Hospital, Japan)
- YD3-6 Outcome of primary radical hysterectomy with adjuvant therapy in bulky early-stage cervical cancer (stage IB2-IIA2): Data from INASGO cancer registry**
Bella Aprilia
(Department of Obstetrics and Gynecology, Faculty of Medicine University of Indonesia, Cipto Mangunkusumo Hospital, Indonesia)

Expert Techniques in Gynecologic Surgery

Date and Time: November 30 (Thursday) 13 : 00~18 : 00

December 1 (Friday) 10 : 00~18 : 00

December 2 (Saturday) 8 : 00~13 : 30

Session Room: 3F 311

These videos are broadcasted repeatedly during the congress.

ETGS1 Abdominal nerve-sparing radical hysterectomy

Tomoyasu Kato

(Department of GYN, National Cancer Center Hospital, Japan)

ETGS2 Nerve-sparing radical hysterectomy with intraoperative electrical nerve stimulation

Hitoshi Niikura

(Department of Gynecology, Tohoku University Hospital, Japan)

ETGS3 Nerve-sparing laparoscopic radical hysterectomy

Satoru Kyo

(Department of Obstetrics and Gynecology, Shimane University Faculty of Medicine, Japan)

ETGS4 Radical hysterectomy for locally advanced cervical cancer with bladder wall adhesion

Toshiaki Saito

(Gynecology Service, National Kyushu Cancer Center, Japan)

ETGS5 Radical hysterectomy (RH) in MIS era

Masaki Mandai

(Department of Gynecology and Obstetrics, Kyoto University Graduate School of Medicine, Japan)

ETGS6 Surgical procedure for para-aortic lymphadenectomy based on the knowledge about the membrane structure of anterior renal fascia

Masanori Kaneuchi

(Department of Obstetrics and Gynecology, Otaru General Hospital, Japan)

ETGS7 An extensive pelvic peritoneal stripping procedure termed “wide resection of the pelvic peritoneum (WRPP)”

Takeshi Motohara

(Department of Obstetrics and Gynecology, Faculty of Life Sciences, Kumamoto University, Japan)

Surgical Film Exhibition

Date and Time: November 30 (Thursday) 13 : 00~18 : 00

December 1 (Friday) 10 : 00~18 : 00

December 2 (Saturday) 8 : 00~13 : 30

Session Room: 3F 311

These videos are broadcasted repeatedly during the conference.

- SF1 High surgical complexity procedures for advanced ovarian cancer**
Shinichi Tate
(Chiba University Hospital, Japan)
- SF2 Super-radical hysterectomy for recurrent cervical cancer**
Hee Seung Kim
(Seoul National University College of Medicine, Korea)
- SF3 The resection of metastatic cardiophrenic lymph node for ovarian carcinoma**
Kyoko Nishikimi
(Chiba University Hospital, Japan)
- SF4 Retroperitoneal lymphadenectomy for ovarian cancer with double inferior vena cava**
Ayumu Matsuoka
(Department of Reproductive Medicine, Graduate School of Medicine, Chiba University, Japan)
- SF5 Surgery for vulvar cancer, basic methods and related skills**
Toshiaki Saito
(Gynecology Service, National Kyushu Cancer Center, Japan)
- SF6 Endometrial cancer sentinel lymph node mapping: Hysteroscopic indocyanine green injection technique**
Jinwei Miao
(Department of Gynecologic Oncology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, China)
- SF7 Laparoscopic-assisted fenestration of vaginal wall in patient with Wunderlich syndrome**
Yusuke Kobayashi
(Department of Obstetrics and Gynecology, Keio University School of Medicine, Japan)
- SF8 Laparoscopic nerve sparing radical hysterectomy for early stage cervical cancer, the endoscopic magnification facilitates better visualization**
Arpitha Anantharaju
(Kidwai Institute of Oncology, India)
- SF9 Complete dissection of paraaortic lymph node using 5-port laparoscopic approach**
Yong-Soon Kwon
(Department of Obstetrics and Gynecology, Ulsan University Hospital, University of Ulsan College of Medicine, Korea)

SF10 Single incision laparoscopic extraperitoneal para-aortic lymph node dissection for surgical staging locally advance cervical cancer

Supachai Raungkaewmanee

(National Cancer Institute Thailand, Thailand)